WithdrawnNot Applicable

Regional Anesthesia to Relief Zoster Pain

Stopped: No enrollement and covid

Vietnam0Started 2020-05-15

Plain-language summary

Pain in Herpes is a serious issue for patients. at the acute phase it is a moderate to severe pain . 30% patients will develop a post herpetic neuralgia this percentage up to 70 % after 60 years old. this post herpetic neuralgia will affect their life. Publication showed the efficiency of regional anesthesia on pain at the acute phase and a recent meta-analysis showed the role of efficient pain relief on the prevention of post herpetic neuralgia. there are still 2 questions to answer: 1/ do we need to perform the regional anesthesia to relief the pain at an early stage of after no response to the medical treatment? 2/ Are repeated blocks more efficient than a single block?

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Acute zona diagnosed by the dermatologist o Acute skin rash with blisters in a limited area on one side of the body * Eruption * Unilateral * On dermatome between C5 and S2 * Age 18 to 85 years old, males and females * American Society of Anesthesiologists Score \[ASA \]grades I \& II * Patient who accepted to participate as volunteers and signed an informed consent Exclusion Criteria: * Psychiatric disease * Central nervous system disease or pre-existing neuropathy * Coagulation abnormalities or anti-coagulant treatment (heparins Anti vit K anti thrombin) * Contra indication to perform a peripheral nerve block or interfascial block * Infection of the skin overlying the puncture site of the block * Allergy to local anaesthetic or prednisolone * Contra indication to prednisolone * ASA III and IV * Morbidity Obese BMI \> 30 * Pregnant woman

What they're measuring

Change in pain intensity between baseline and the end of treatment

Timeframe: baseline - end of treatment at day 30

Trial details

NCT IDNCT04133142

SponsorVinmec Healthcare System

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-11-12